Compositions and methods for cardiovascular disease

a cardiovascular disease and composition technology, applied in the field of cardiovascular disease compositions and methods, can solve the problems of ineffective and practical methods of inhibiting bmp signals via soluble receptors, endogenous inhibitors such as noggin and follistatin, and limited specificity of endogenous inhibitors such as follistatin for ligand subclasses, so as to reduce the circulating levels of apob-100 and/or ldl and/or total cholesterol,

Inactive Publication Date: 2014-02-06
THE GENERAL HOSPITAL CORP
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0109]In another aspect, the invention provides a method of inhibiting BMP-induced phosphorylation of SMAD1 / 5 / 8, comprising contacting a cell with a compound as disclosed herein. In certain embodiments, the method reduces the circulating levels of ApoB-100 and / or LDL and / or total cholesterol in a subject that has levels of ApoB-100 and / or LDL and / or total cholesterol that are abnormally high or that increase a patient's risk of developing a disease or unwanted medical condition. In certain embodiments, the method of reducing circulating levels of ApoB-100 and / or LDL and / or total cholesterol in a subject reduces the risk of primary or secondary cardiovascular events. In certain embodiments, the method treats or prevents a disease or condition in a subject that would benefit by inhibition of Bone Morphogenetic Protein (BMP) signaling. In certain embodiments, the disease or condition is selected from pulmonary hypertension; hereditary hemorrhagic telangectasia syndrome; cardiac valvular malformations; cardiac structural malformations; fibrodysplasia ossificans progressive; juvenile familial polyposis syndrome; parathyroid disease; cancer (e.g., breast carcinoma, prostate carcinoma, renal cell carcinoma, bone metastasis, lung metastasis, osteosarcoma, and multiple myeloma); anemia; vascular calcification; vascular inflammation; atherosclerosis; acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; diseases, disorders, or syndromes caused by hyperlipidemia; valve calcification; renal osteodystrophy; inflammatory disorders (e.g., ankylosing spondylitis); infections with viruses; bacteria; fungi; tuberculosis; and parasites.
[0111]In another aspect, the invention provides a method of reducing primary and secondary cardiovascular events arising from coronary, cerebral, or peripheral vascular disease in a subject, comprising administering an effective amount of a compound as disclosed herein.

Problems solved by technology

Given the tremendous structural diversity of the BMP and TGF-β superfamily at the level of ligands (>25 distinct ligands at present) and receptors (four type I and three type II receptors that recognize BMPs), and the heterotetrameric manner of receptor binding, traditional approaches for inhibiting BMP signals via soluble receptors, endogenous inhibitors, or neutralizing antibodies are not practical or effective.
Endogenous inhibitors such as noggin and follistatin have limited specificity for ligand subclasses.
Neutralizing antibodies are specific for particular ligands or receptors and are also limited by the structural diversity of this signaling system.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for cardiovascular disease
  • Compositions and methods for cardiovascular disease
  • Compositions and methods for cardiovascular disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0287]To elucidate the role of BMP signaling in vascular calcification and atherogenesis, BMP signaling was inhibited in vivo using small molecule and recombinant protein approaches. Mice deficient in the low-density lipoprotein receptor (LDLR− / −) fed a high fat diet (HFD) were studied. (Ishibashi, S., Goldstein, J. L., Brown, M. S., Herz, J. & Burns, D. K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 93, 1885-1893 (1994).) These mice developed atheroma within 4-6 weeks followed by intimal and medial calcification by 16-20 weeks (FIG. 1a). At 20 weeks, there was extensive vascular calcification (as reflected by fluorescence labeled bisphosphonate uptake, Alizarin red staining and Von Kossa staining), inflammation (as reflected by cathepsin mediated cleavage of a near infrared imaging probe) and abundant lipid accumulation (as reflected by Oil Red O) in the aorta and large-vessel branches. (FIG. 2a-d)

[0288]...

example 2

Establishment of a Mouse Model of Atheromatous and Vascular Calcific Disease

[0316]The inventors' objectives are to demonstrate the effect of pharmacologic BMP inhibition upon the development of (i) atheromatous disease burden, and (ii) vascular calcification in an accepted animal model of atherosclerosis, in order to provide potential proof-of-concept that BMP inhibition can be an effective strategy for preventing atherosclerosis or limiting its progression.

[0317]BMPs are multifunctional protein ligands which form a subset of the transforming growth factor-β (TGF-β) family of signaling proteins (Feng, X. H. & Derynck, R., Annu Rev Cell Dev Biol 21, 659-693 (2005)). BMPs, originally identified by their ability to induce ectopic bone formation, serve broad roles in gastrulation, developmental patterning, and organ formation. In the adult organism, BMP signals serve principally to mediate injury repair and inflammation. Aberrant BMP signaling may contribute to a number of acquired dise...

example 3

A BMP Inhibitor can Inhibit the Development of Vascular Calcification and Macrophage-Mediated Inflammation Associated with Atheromatous Disease

[0320]LDLr− / − mice were treated with a BMP inhibitor positive control compound (compound 13, 2.5 mg / kg / d intraperitoneally) or vehicle (saline) for 20 weeks following the initiation of a high fat diet. Mice were injected with Osteosense (to label sites of bone-forming activity via osteoblast binding of this probe) and Prosense (to label sites of macrophage-mediated inflammation). Aortae were explanted and subjected to fluorescence reflectance imaging (LICOR Odyssey imager). Fluorescence in the 700 nm channel (Osteosense) revealed diminished fluorescence in the aortae of the BMP inhibitor positive control compound-treated as compared to vehicle-treated mice (data not shown). Significant differences in macrophage and osteoblast staining were observed throughout the vascular tree in a cohort of treated and control mice (n=10 each). In examining ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pKaaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to reduce circulating levels of ApoB-100 or LDL. These compounds may also be used to treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of priority to U.S. Provisional Patent Application No. 61 / 434,932, filed Jan. 21, 2011, which application is hereby incorporated by reference in its entiretySTATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was supported in part by the United States Government under National Institutes of Health Grant NIH / NHLBI 5K08HL079943. The Government may have certain rights in this invention.BACKGROUND OF THE INVENTION[0003]Signaling involving the Transforming Growth Factor β (TGF-β) superfamily of ligands is central to a wide range of cellular processes, including cell growth, differentiation, and apoptosis. TGF-β signaling involves binding of a TGF-β ligand to a type II receptor (a serine / threonine kinase), which recruits and phosphorylates a type I receptor. The type I receptor then phosphorylates a receptor-regulated SMAD (R-SMAD; e.g., SMAD1, SMAD2, SMAD3, SMAD5, SMAD8 or SMAD9), which binds to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D487/04C07D471/04
CPCC07D471/04C07D487/04A61K31/519A61P1/16A61P3/06A61P9/00A61P9/10A61K31/4709A61K31/496A61K31/5377
Inventor YU, PAUL B.DERWALL, MATTHIASBLOCH, KENNETH D.MALHOTRA, RAJEEV
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap